APO Research
Talk to an analyst

APO RESEARCH · REPORT

Infectious Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Infectious Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025192 pages

Choose your research edition.

Industry ResearchInfectious Vaccines Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Infectious Vaccines Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Infectious Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Infectious Vaccines Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Infectious Vaccines Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Infectious Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Infectious Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Infectious Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Infectious Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Infectious Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Infectious Vaccines include Sanofi Pasteur (France), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), MedImmune LLC (U.S.), Emergent Bio Solutions Inc. (U.S.) and CSL Limited (Australia), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Infectious Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Infectious Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Infectious Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Infectious Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Infectious Vaccines Segment by Company

Sanofi Pasteur (France)

Johnson and Johnson (U.S.)

Novartis AG (Switzerland)

Merck and Company (U.S.)

Pfizer Inc. (U.S.)

GlaxoSmithKline plc. (U.K.)

MedImmune LLC (U.S.)

Emergent Bio Solutions Inc. (U.S.)

CSL Limited (Australia)

Bavarian Nordic (Denmark)

Infectious Vaccines Segment by Type

Preventive Vaccine

Therapeutic Vaccine

Infectious Vaccines Segment by Application

Adults

Pediatrics

Infectious Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Infectious Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Infectious Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Infectious Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Infectious Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Infectious Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Infectious Vaccines Industry Trends Table 2. Infectious Vaccines Industry Drivers Table 3. Infectious Vaccines Industry Opportunities and Challenges Table 4. Infectious Vaccines Industry Restraints Table 5. Global Infectious Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Infectious Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Infectious Vaccines Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Infectious Vaccines Sales Market Share by Manufacturers Table 9. Global Infectious Vaccines Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Infectious Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Infectious Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Infectious Vaccines Manufacturers, Product Type & Application Table 13. Global Infectious Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Infectious Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Preventive Vaccine Table 17. Major Manufacturers of Therapeutic Vaccine Table 18. Global Infectious Vaccines Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Infectious Vaccines Sales by Type (2021-2026) & (k units) Table 20. Global Infectious Vaccines Sales by Type (2027-2032) & (k units) Table 21. Global Infectious Vaccines Sales Market Share by Type (2021-2026) Table 22. Global Infectious Vaccines Sales Market Share by Type (2027-2032) Table 23. Global Infectious Vaccines Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Infectious Vaccines Revenue by Type (2021-2026) & (k units) Table 25. Global Infectious Vaccines Revenue by Type (2027-2032) & (k units) Table 26. Global Infectious Vaccines Revenue Market Share by Type (2021-2026) Table 27. Global Infectious Vaccines Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Adults Table 29. Major Manufacturers of Pediatrics Table 30. Global Infectious Vaccines Sales by Application 2021 VS 2025 VS 2032 (k units) Table 31. Global Infectious Vaccines Sales by Application (2021-2026) & (k units) Table 32. Global Infectious Vaccines Sales by Application (2027-2032) & (k units) Table 33. Global Infectious Vaccines Sales Market Share by Application (2021-2026) Table 34. Global Infectious Vaccines Sales Market Share by Application (2027-2032) Table 35. Global Infectious Vaccines Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Infectious Vaccines Revenue by Application (2021-2026) & (k units) Table 37. Global Infectious Vaccines Revenue by Application (2027-2032) & (k units) Table 38. Global Infectious Vaccines Revenue Market Share by Application (2021-2026) Table 39. Global Infectious Vaccines Revenue Market Share by Application (2027-2032) Table 40. Global Infectious Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 41. Global Infectious Vaccines Sales by Region (2021-2026) & (k units) Table 42. Global Infectious Vaccines Sales Market Share by Region (2021-2026) Table 43. Global Infectious Vaccines Sales Forecasted by Region (2027-2032) & (k units) Table 44. Global Infectious Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Infectious Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 46. North America Infectious Vaccines Sales by Country (2021-2026) & (k units) Table 47. North America Infectious Vaccines Sales by Country (2027-2032) & (k units) Table 48. Europe Infectious Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. Europe Infectious Vaccines Sales by Country (2021-2026) & (k units) Table 50. Europe Infectious Vaccines Sales by Country (2027-2032) & (k units) Table 51. Asia Pacific Infectious Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Asia Pacific Infectious Vaccines Sales by Country (2021-2026) & (k units) Table 53. Asia Pacific Infectious Vaccines Sales by Country (2027-2032) & (k units) Table 54. South America, Middle East and Africa Infectious Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. South America, Middle East and Africa Infectious Vaccines Sales by Country (2021-2026) & (k units) Table 56. South America, Middle East and Africa Infectious Vaccines Sales by Country (2027-2032) & (k units) Table 57. Global Infectious Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Infectious Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Infectious Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Infectious Vaccines Revenue Market Share by Region (2021-2026) Table 61. Global Infectious Vaccines Revenue Market Share by Region (2027-2032) Table 62. Sanofi Pasteur (France) Company Information Table 63. Sanofi Pasteur (France) Business Overview Table 64. Sanofi Pasteur (France) Infectious Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Sanofi Pasteur (France) Infectious Vaccines Product Portfolio Table 66. Sanofi Pasteur (France) Recent Development Table 67. Johnson and Johnson (U.S.) Company Information Table 68. Johnson and Johnson (U.S.) Business Overview Table 69. Johnson and Johnson (U.S.) Infectious Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio Table 71. Johnson and Johnson (U.S.) Recent Development Table 72. Novartis AG (Switzerland) Company Information Table 73. Novartis AG (Switzerland) Business Overview Table 74. Novartis AG (Switzerland) Infectious Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Novartis AG (Switzerland) Infectious Vaccines Product Portfolio Table 76. Novartis AG (Switzerland) Recent Development Table 77. Merck and Company (U.S.) Company Information Table 78. Merck and Company (U.S.) Business Overview Table 79. Merck and Company (U.S.) Infectious Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Merck and Company (U.S.) Infectious Vaccines Product Portfolio Table 81. Merck and Company (U.S.) Recent Development Table 82. Pfizer Inc. (U.S.) Company Information Table 83. Pfizer Inc. (U.S.) Business Overview Table 84. Pfizer Inc. (U.S.) Infectious Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio Table 86. Pfizer Inc. (U.S.) Recent Development Table 87. GlaxoSmithKline plc. (U.K.) Company Information Table 88. GlaxoSmithKline plc. (U.K.) Business Overview Table 89. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio Table 91. GlaxoSmithKline plc. (U.K.) Recent Development Table 92. MedImmune LLC (U.S.) Company Information Table 93. MedImmune LLC (U.S.) Business Overview Table 94. MedImmune LLC (U.S.) Infectious Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio Table 96. MedImmune LLC (U.S.) Recent Development Table 97. Emergent Bio Solutions Inc. (U.S.) Company Information Table 98. Emergent Bio Solutions Inc. (U.S.) Business Overview Table 99. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio Table 101. Emergent Bio Solutions Inc. (U.S.) Recent Development Table 102. CSL Limited (Australia) Company Information Table 103. CSL Limited (Australia) Business Overview Table 104. CSL Limited (Australia) Infectious Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. CSL Limited (Australia) Infectious Vaccines Product Portfolio Table 106. CSL Limited (Australia) Recent Development Table 107. Bavarian Nordic (Denmark) Company Information Table 108. Bavarian Nordic (Denmark) Business Overview Table 109. Bavarian Nordic (Denmark) Infectious Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio Table 111. Bavarian Nordic (Denmark) Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Infectious Vaccines Distributors List Table 115. Infectious Vaccines Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Infectious Vaccines Product Image Figure 2. Global Infectious Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Infectious Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Infectious Vaccines Sales (2021-2032) & (k units) Figure 5. Global Infectious Vaccines Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Infectious Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Preventive Vaccine Image Figure 9. Therapeutic Vaccine Image Figure 10. Global Infectious Vaccines Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Infectious Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Infectious Vaccines Sales Market Share by Type (2021-2032) Figure 13. Global Infectious Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Infectious Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Infectious Vaccines Revenue Market Share by Type (2021-2032) Figure 16. Adults Image Figure 17. Pediatrics Image Figure 18. Global Infectious Vaccines Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Infectious Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Infectious Vaccines Sales Market Share by Application (2021-2032) Figure 21. Global Infectious Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Infectious Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Infectious Vaccines Revenue Market Share by Application (2021-2032) Figure 24. North America Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 25. North America Infectious Vaccines Sales Market Share by Country (2021-2032) Figure 26. U.S. Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 27. Canada Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 28. Mexico Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 29. Europe Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Infectious Vaccines Sales Market Share by Country (2021-2032) Figure 31. Germany Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 32. France Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 33. U.K. Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 34. Italy Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 35. Netherlands Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 36. Asia Pacific Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Infectious Vaccines Sales Market Share by Country (2021-2032) Figure 38. China Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 39. Japan Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 40. South Korea Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 41. Southeast Asia Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 42. India Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 43. Australia Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 44. South America, Middle East and Africa Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Infectious Vaccines Sales Market Share by Country (2021-2032) Figure 46. Brazil Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Africa Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 48. Saudi Arabia Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 49. Turkey Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 50. Argentina Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 51. UAE Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 52. Egypt Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 53. Chile Infectious Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 54. Global Infectious Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Infectious Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Infectious Vaccines Revenue (2021-2032) & (US$ Million) Figure 57. North America Infectious Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Infectious Vaccines Revenue (2021-2032) & (US$ Million) Figure 59. Europe Infectious Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Infectious Vaccines Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Infectious Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Infectious Vaccines Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Infectious Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Infectious Vaccines Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Infectious Vaccines Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Preventive Vaccine
  • Therapeutic Vaccine
Applications
  • Adults
  • Pediatrics
Companies covered
  • Sanofi Pasteur (France)
  • Johnson and Johnson (U.S.)
  • Novartis AG (Switzerland)
  • Merck and Company (U.S.)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc. (U.K.)
  • MedImmune LLC (U.S.)
  • Emergent Bio Solutions Inc. (U.S.)
  • CSL Limited (Australia)
  • Bavarian Nordic (Denmark)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Infectious Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Infectious Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Infectious Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Infectious Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Infectious Vaccines Market Dynamics
  1. 2.1 Infectious Vaccines Industry Trends
  2. 2.2 Infectious Vaccines Industry Drivers
  3. 2.3 Infectious Vaccines Industry Opportunities and Challenges
  4. 2.4 Infectious Vaccines Industry Restraints
3 Infectious Vaccines Market by Manufacturers
  1. 3.1 Global Infectious Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Infectious Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Infectious Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Infectious Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Infectious Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Infectious Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Infectious Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Infectious Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Infectious Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Infectious Vaccines Tier 1, Tier 2, and Tier 3
4 Infectious Vaccines Market by Type
  1. 4.1 Infectious Vaccines Type Introduction
  2. 4.1.1 Preventive Vaccine
  3. 4.1.2 Therapeutic Vaccine
  4. 4.2 Global Infectious Vaccines Sales by Type
  5. 4.2.1 Global Infectious Vaccines Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Infectious Vaccines Sales by Type (2021-2032)
  7. 4.2.3 Global Infectious Vaccines Sales Market Share by Type (2021-2032)
  8. 4.3 Global Infectious Vaccines Revenue by Type
  9. 4.3.1 Global Infectious Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Infectious Vaccines Revenue by Type (2021-2032)
  11. 4.3.3 Global Infectious Vaccines Revenue Market Share by Type (2021-2032)
5 Infectious Vaccines Market by Application
  1. 5.1 Infectious Vaccines Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Pediatrics
  4. 5.2 Global Infectious Vaccines Sales by Application
  5. 5.2.1 Global Infectious Vaccines Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Infectious Vaccines Sales by Application (2021-2032)
  7. 5.2.3 Global Infectious Vaccines Sales Market Share by Application (2021-2032)
  8. 5.3 Global Infectious Vaccines Revenue by Application
  9. 5.3.1 Global Infectious Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Infectious Vaccines Revenue by Application (2021-2032)
  11. 5.3.3 Global Infectious Vaccines Revenue Market Share by Application (2021-2032)
6 Global Infectious Vaccines Sales by Region
  1. 6.1 Global Infectious Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Infectious Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Infectious Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Infectious Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Infectious Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Infectious Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Infectious Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Infectious Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Infectious Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Infectious Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Infectious Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Infectious Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Infectious Vaccines Revenue by Region
  1. 7.1 Global Infectious Vaccines Revenue by Region
  2. 7.1.1 Global Infectious Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Infectious Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Infectious Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Infectious Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Infectious Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Infectious Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Infectious Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Infectious Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Infectious Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Infectious Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Infectious Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Infectious Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi Pasteur (France)
  2. 8.1.1 Sanofi Pasteur (France) Company Information
  3. 8.1.2 Sanofi Pasteur (France) Business Overview
  4. 8.1.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Pasteur (France) Infectious Vaccines Product Portfolio
  6. 8.1.5 Sanofi Pasteur (France) Recent Developments
  7. 8.2 Johnson and Johnson (U.S.)
  8. 8.2.1 Johnson and Johnson (U.S.) Company Information
  9. 8.2.2 Johnson and Johnson (U.S.) Business Overview
  10. 8.2.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio
  12. 8.2.5 Johnson and Johnson (U.S.) Recent Developments
  13. 8.3 Novartis AG (Switzerland)
  14. 8.3.1 Novartis AG (Switzerland) Company Information
  15. 8.3.2 Novartis AG (Switzerland) Business Overview
  16. 8.3.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis AG (Switzerland) Infectious Vaccines Product Portfolio
  18. 8.3.5 Novartis AG (Switzerland) Recent Developments
  19. 8.4 Merck and Company (U.S.)
  20. 8.4.1 Merck and Company (U.S.) Company Information
  21. 8.4.2 Merck and Company (U.S.) Business Overview
  22. 8.4.3 Merck and Company (U.S.) Infectious Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck and Company (U.S.) Infectious Vaccines Product Portfolio
  24. 8.4.5 Merck and Company (U.S.) Recent Developments
  25. 8.5 Pfizer Inc. (U.S.)
  26. 8.5.1 Pfizer Inc. (U.S.) Company Information
  27. 8.5.2 Pfizer Inc. (U.S.) Business Overview
  28. 8.5.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio
  30. 8.5.5 Pfizer Inc. (U.S.) Recent Developments
  31. 8.6 GlaxoSmithKline plc. (U.K.)
  32. 8.6.1 GlaxoSmithKline plc. (U.K.) Company Information
  33. 8.6.2 GlaxoSmithKline plc. (U.K.) Business Overview
  34. 8.6.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio
  36. 8.6.5 GlaxoSmithKline plc. (U.K.) Recent Developments
  37. 8.7 MedImmune LLC (U.S.)
  38. 8.7.1 MedImmune LLC (U.S.) Company Information
  39. 8.7.2 MedImmune LLC (U.S.) Business Overview
  40. 8.7.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio
  42. 8.7.5 MedImmune LLC (U.S.) Recent Developments
  43. 8.8 Emergent Bio Solutions Inc. (U.S.)
  44. 8.8.1 Emergent Bio Solutions Inc. (U.S.) Company Information
  45. 8.8.2 Emergent Bio Solutions Inc. (U.S.) Business Overview
  46. 8.8.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio
  48. 8.8.5 Emergent Bio Solutions Inc. (U.S.) Recent Developments
  49. 8.9 CSL Limited (Australia)
  50. 8.9.1 CSL Limited (Australia) Company Information
  51. 8.9.2 CSL Limited (Australia) Business Overview
  52. 8.9.3 CSL Limited (Australia) Infectious Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CSL Limited (Australia) Infectious Vaccines Product Portfolio
  54. 8.9.5 CSL Limited (Australia) Recent Developments
  55. 8.10 Bavarian Nordic (Denmark)
  56. 8.10.1 Bavarian Nordic (Denmark) Company Information
  57. 8.10.2 Bavarian Nordic (Denmark) Business Overview
  58. 8.10.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio
  60. 8.10.5 Bavarian Nordic (Denmark) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Infectious Vaccines Value Chain Analysis
  2. 9.1.1 Infectious Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Infectious Vaccines Production Mode & Process
  6. 9.2 Infectious Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Infectious Vaccines Distributors
  9. 9.2.3 Infectious Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst